What Is SS-31?
SS-31, also known as Elamipretide, is a synthetic mitochondria-targeting peptide studied for its potential role in supporting mitochondrial function, cellular energy production, and oxidative stress balance.
Unlike many peptides that act through hormone pathways or growth-factor signaling, SS-31 is primarily discussed for its interaction with the inner mitochondrial membrane, especially cardiolipin, a phospholipid involved in mitochondrial structure and energy production.
SS-31 has been studied in areas such as mitochondrial disease, aging-related mitochondrial decline, muscle function, heart health, kidney injury, neurodegenerative models, and cellular stress research. Elamipretide has also reached advanced clinical development, including research in Barth syndrome and primary mitochondrial myopathy.
SS-31 At A Glance
| Category | Details |
|---|---|
| Compound Name | SS-31 |
| Other Names | Elamipretide, Bendavia, MTP-131 |
| Peptide Type | Mitochondria-targeting tetrapeptide |
| Primary Area of Interest | Mitochondrial function and cellular energy |
| Commonly Discussed Use | Fatigue, recovery, mitochondrial support, cellular health research |
| Typical Route Discussed | Subcutaneous injection |
| Common Research Range | 1 mg to 5 mg daily |
| Common Cycle Length | 4 to 12 weeks |
| Onset Often Discussed | Gradual, often over several weeks |
| Storage | Refrigerated after reconstitution |
How SS-31 Works
SS-31 is best known for its mitochondrial-targeting activity. It is believed to concentrate around the inner mitochondrial membrane, where it interacts with cardiolipin.
Cardiolipin plays an important role in maintaining mitochondrial membrane structure, electron transport chain function, and ATP production. SS-31 has been studied for its ability to support mitochondrial respiration, reduce oxidative stress, and improve mitochondrial efficiency in certain models.
Mitochondrial Membrane Support
SS-31 may help stabilize the inner mitochondrial membrane and support more efficient energy production.
Oxidative Stress Balance
Research suggests SS-31 may help reduce excessive reactive oxygen species, commonly referred to as ROS, which are associated with cellular stress and mitochondrial dysfunction.
Cellular Energy Production
Because mitochondria are responsible for producing ATP, SS-31 is often discussed in the context of energy, endurance, recovery, and fatigue-related research.
Commonly Discussed SS-31 Protocols
The following protocols are commonly discussed in research and educational settings only. They are not medical recommendations.
| Protocol Type | Commonly Discussed Amount | Frequency | Common Duration |
|---|---|---|---|
| Conservative Protocol | 1 mg | Daily | 4 to 8 weeks |
| Moderate Protocol | 2 mg to 3 mg | Daily | 6 to 12 weeks |
| Higher Research Protocol | 4 mg to 5 mg | Daily | 8 to 12 weeks |
| Extended Support Approach | 1 mg to 2 mg | Daily or 5 days per week | 8 to 16 weeks |
Many users discussing SS-31 prefer starting low, especially because mitochondrial-support compounds may produce subtle effects that build gradually rather than immediate noticeable changes.
What Users Commonly Report
User reports vary widely, and SS-31 is usually described as a gradual peptide rather than an acute, fast-feeling compound.
| Timeline | Commonly Discussed Reports |
|---|---|
| Week 1 | Subtle changes, little noticeable effect for some users |
| Weeks 2 to 4 | Improved daily energy, less fatigue, better recovery |
| Weeks 4 to 8 | Better endurance, improved exercise tolerance, more stable energy |
| Weeks 8 to 12 | More noticeable mitochondrial-support effects in longer protocols |
Potential Benefits
Commonly discussed SS-31 benefits include:
- Mitochondrial support
- Improved cellular energy production
- Reduced oxidative stress
- Better exercise tolerance
- Improved recovery
- Support for fatigue-related research
- Heart, kidney, brain, and muscle-related research interest
- Healthy aging and longevity-related research interest
Potential Side Effects
SS-31 is generally discussed as being well tolerated, but side effects may still occur.
Potentially reported side effects include:
- Injection-site irritation
- Redness or tenderness
- Headache
- Nausea
- Dizziness
- Fatigue
- Temporary changes in energy or sleep
- Mild flu-like feeling in some users
Anyone with a diagnosed mitochondrial disorder, heart condition, kidney disease, neurological condition, or who is using prescription medication should speak with a qualified medical professional before considering SS-31.
SS-31 vs MOTS-c
SS-31 and MOTS-c are both commonly discussed in mitochondrial health circles, but they are not the same type of peptide.
SS-31 is primarily discussed for direct mitochondrial membrane support and cardiolipin interaction.
MOTS-c is more commonly discussed in relation to metabolic signaling, glucose metabolism, exercise adaptation, and AMPK-related pathways.
Because of this, SS-31 is often viewed as more mitochondrial-structure focused, while MOTS-c is often viewed as more metabolic-signaling focused.
Frequently Asked Questions
Is SS-31 the same as Elamipretide?
Yes. SS-31 is commonly known as Elamipretide. It has also been referred to as Bendavia and MTP-131 in research settings.
How long does SS-31 take to work?
Many users describe SS-31 as gradual. Some report subtle improvements within 2 to 4 weeks, while others notice more meaningful changes after 6 to 12 weeks.
Is SS-31 used for energy?
SS-31 is often discussed for mitochondrial support and cellular energy research. However, it is not a stimulant and should not be expected to produce a caffeine-like effect.
Is SS-31 commonly injected subcutaneously?
Yes, subcutaneous injection is the most commonly discussed route in research and user protocols.
Can SS-31 be combined with other mitochondrial peptides?
SS-31 is often discussed alongside MOTS-c, NAD+, 5-Amino-1MQ, and other mitochondrial or metabolic-support compounds, depending on the research goal.
Is SS-31 FDA approved?
Elamipretide received FDA accelerated approval in 2025 as Forzinity for Barth syndrome in patients weighing at least 30 kg. This approval is specific to that rare medical condition and does not mean SS-31 is broadly approved for general wellness, anti-aging, fatigue, or performance use.
Brief Research Summary
SS-31 has been studied for its ability to target mitochondria and interact with cardiolipin in the inner mitochondrial membrane. Research suggests it may support mitochondrial respiration, electron transport chain efficiency, ATP production, and oxidative stress balance.
Clinical research has explored Elamipretide in Barth syndrome, primary mitochondrial myopathy, heart failure, and other mitochondrial-related conditions. Results have been mixed depending on the condition and trial design, but SS-31 remains one of the more widely studied mitochondria-targeting peptides.